Introduction {#section1-2333794X20901932}
============

Survival of preterm babies has increased worldwide,^[@bibr1-2333794X20901932]^ with a concomitant decline in severe neonatal morbidity. However, the risk of neurodevelopmental disabilities remains high in children who were born preterm.^[@bibr2-2333794X20901932]^ Rate of survival with neurodevelopmental impairment increased over time.^[@bibr3-2333794X20901932]^ The highest rate of mortality and morbidity had been reported in those infants born weighing \<1000 g. Risk factors identified to affect neurodevelopmental outcomes include severe intraventricular hemorrhage, cystic periventricular leukomalacia, and congenital malformation in previous study.^[@bibr2-2333794X20901932],[@bibr4-2333794X20901932]^

We retrospectively reviewed a cohort of extremely low-birth-weight (ELBW) babies born at a tertiary perinatal center in Hong Kong (Queen Mary Hospital \[QMH\]) during the period of 2008 to 2015. We explored if there is any time trend in survival, major morbidity, and short-term neurodevelopmental outcomes, and we identified significant factors that might account for any observable changes.

Methods {#section2-2333794X20901932}
=======

Study Population and Data Collection {#section3-2333794X20901932}
------------------------------------

The study was conducted at QMH, Hong Kong. QMH is a regional hospital with an annual delivery rate of around 3500 to 4500 and is also a tertiary perinatal center that receives referrals requiring complicated perinatal care.

We included infants with birth weight ≤1000 g born at QMH between January 1, 2008, and December 31, 2015. Infants born outside of QMH were excluded. Data were retrieved from the Clinical Data Analysis and Reporting System (CDARS) under Hospital Authority and Vermont Oxford Network database. University of Hong Kong/Hospital Authority Hong Kong West Cluster Institutional Review Board (IRB) approval was obtained.

Baseline infant and maternal characteristics including birth weight, gestational age (GA), sex, plurality of pregnancy, small for gestational age (SGA; defined as birth weight of \<10th percentile for gender and GA), use of antenatal steroid, and Apgar score ≤3 at 1 minute of life were recorded. Neonatal medical conditions including use of surfactant for respiratory distress syndrome (RDS), severe intraventricular hemorrhage (IVH; defined as grade 3 or 4 IVH), patent ductus arteriosus requiring ligation, necrotizing enterocolitis (NEC; defined as stage ≥2 of Bell's criteria), early-onset sepsis (defined as bacterial pathogen identified from a blood and/or cerebrospinal fluid culture within 72 hours of life), severe retinopathy of prematurity (ROP; defined as stage III or above according to international classification), chronic lung disease (defined as supplemental oxygen use at a postmenstrual age of 36 weeks), and home oxygen dependency were studied. Duration of mechanical ventilation and length of hospital stay among survivors were also included.

Primary outcome was survival on discharge. Secondary outcomes included neurodevelopmental outcomes and growth failure at a corrected age of 18 to 24 months. Neurodevelopmental outcomes were evaluated using the Griffiths Mental Developmental Scales--Extended Revised by pediatric neurologist or developmental pediatrician. Infants were considered to have neurodevelopmental or behavioral problem if they had at least one of the following conditions: cognitive impairment (Griffiths Developmental Quotient \[DQ\] \<2 standard deviation \[SD\] overall or at least in one subscale), cerebral palsy, profound visual or hearing impairment, autism spectrum disorder, and attention deficit hyperactivity disorder. Growth failure was defined as growth parameters (body weight, head circumference, and body height) of less than third percentile for gender and age.

Need for special education service referral and presence of epilepsy at the corrected age of 18 to 24 months were also examined.

Interval of neurological/developmental follow-up depends on any abnormality being detected; if assessment is normal at a corrected age of 18 to 24 months, child will be seen again at around 4 to 5 years old.

Statistical Analysis {#section4-2333794X20901932}
--------------------

Demographic data were expressed in mean, median, and percentages when appropriate. Chi-square test was used for categorical variables and median test for continuous variables. The relationships between multiple risk factors with survival, neurodevelopmental outcomes, and growth failure were analyzed by either Cox regression or univariate logistic regression analysis. If more than one factor is being identified, further analysis using multiple logistic regression will be performed. We also compared the birth-year period (2008-2015) with our previous study from 1993 to 2002.^[@bibr5-2333794X20901932]^ However, due to unavailability of some of the raw data in the cohort of 1993 to 2002, comparisons using the above-mentioned statistical analysis were not possible in some parameters. All *P* values were 2-tailed, and a *P* value of \<.05 was considered statistically significant. SPSS 24.0 was used for all statistical analyses.

Ethical Approval and Informed Consent {#section5-2333794X20901932}
-------------------------------------

This study received IRB approval by the IRB of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (Approval \#UW 19-376). According to the retrospective nature of the study, the IRB waived the requirement for informed consent.

Results {#section6-2333794X20901932}
=======

Demographic Data and Perinatal Characteristics {#section7-2333794X20901932}
----------------------------------------------

The perinatal characteristics of the study cohort are shown in [Table 1](#table1-2333794X20901932){ref-type="table"}. Two hundred seventeen infants weighing ≤1000 g were delivered during the study period of 2008 to 2015. Mean GA was 26.5 ± 2.3 weeks, with a mean birth weight of 762 ± 148 g. One hundred twelve (51.6%) were male infants, 68 (31.3%) were born via multiple pregnancy, and 63 (29%) of them were born SGA. Two hundred (92.2%) infants were given antenatal steroid before birth, and 61 (28.1%) were born with Apgar score ≤3 at 1 minute of life.

###### 

Perinatal Characteristics.

![](10.1177_2333794X20901932-table1)

                                       1993-2002       2008-2015    *P*
  ------------------------------------ --------------- ------------ -------
  Number of live births                234             217          
  Birth weight (g)                                                  N/A
   Mean ± SD                           778 (SD N/A)    762 ± 148    
   Range                               450-1000        345-1000     
  Gestational age (weeks), mean ± SD   26.5 (SD N/A)   26.5 ± 2.3   N/A
  Male sex, n (%)                      122 (52.1)      112 (51.6)   .99
  Multiple pregnancy, n (%)            71 (30.3)       68 (31.3)    .90
  SGA, n (%)                           98 (41.9)       63 (29.0)    .01
  Use of antenatal steroid, n (%)      121 (51.7)      200 (92.2)   .0001
  One-minute Apgar score ≤3, n (%)     89 (38)         61 (28.1)    .03

Abbreviations: SD, standard deviation; SGA, small for gestational age; N/A, not available.

### Comparison Between 1993-2002 and 2008-2015 Birth Cohorts {#section8-2333794X20901932}

The proportion of babies born SGA and with Apgar score at 1 minute of life ≤3 were significantly lower in the 2008 to 2015 cohort (*P* = .01 and *P* = .03, respectively), while the use of antenatal steroid was significantly higher (*P* = .0001) than in the 1993 to 2002 cohort ([Table 1](#table1-2333794X20901932){ref-type="table"}).

Survival {#section9-2333794X20901932}
--------

[Figure 1](#fig1-2333794X20901932){ref-type="fig"} shows the survival curve for birth years 2008 to 2015, with an overall survival of 81.1% (176/217 infants survived). [Table 2](#table2-2333794X20901932){ref-type="table"} shows the survival rate on discharge. Survival on discharge was highest in the group with a birth weight \>750 g (92.7%, 102/110 infants survived), and lowest in the group with the lowest birth weight of ≤500 g (42.9%, 3/7 infants survived). Risk factors identified affecting survival using Cox regression analysis included a lower birth weight, presence of severe IVH, and early-onset sepsis (all *P* = .000).

![Survival curve of extremely low-birth-weight infants.](10.1177_2333794X20901932-fig1){#fig1-2333794X20901932}

###### 

Comparison of Survival of Extremely Low-Birth-Weight Infants in 1993 to 2002 Versus 2008 to 2015 in Different Birth Weight Subgroups.

![](10.1177_2333794X20901932-table2)

  Birth Weight (g)   Survival on Discharge   Survival on Discharge   *P*
  ------------------ ----------------------- ----------------------- -----
  500 g or below     4/8 (50%)               3/7 (42.9%)             .78
  501-750 g          46/87 (52.9%)           71/100 (71%)            .02
  751-1000 g         117/139 (84.2%)         102/110 (92.7%)         .06
  Overall            167/234 (71.4%)         176/217 (81.1%)         .02

### Comparison Between 1993-2002 and 2008-2015 Birth Cohorts {#section10-2333794X20901932}

There was significantly higher overall survival rate in recent years (2008-2015) compared with that in 1993-2002 (*P* = .02; [Table 2](#table2-2333794X20901932){ref-type="table"}). When we categorized the survival according to birth weight, the improvement was most significant in the 501 to 750 g subgroup (*P* = .02).

Neonatal Morbidity {#section11-2333794X20901932}
------------------

Major neonatal morbidities were shown in [Table 3](#table3-2333794X20901932){ref-type="table"}. A total of 85.3% (185/217 infants) were given surfactant for RDS, 63.1% (111/176 infants) were diagnosed to have chronic lung disease, and 29.5% (52/176 infants) were discharged home with oxygen. A total of 10.8% (19/176 infants) underwent patent ductus arteriosus ligation, 19.3% (34/176 infants) had severe ROP, 3.7% (8/217 infants) suffered from early-onset sepsis, 12% (26/217 infants) had severe IVH, and 7.8% (17/217 infants) had NEC (12/17 infants requiring surgery for NEC).

###### 

Comparison of Neonatal Morbidities in 1993-2002 Versus 2008-2015.

![](10.1177_2333794X20901932-table3)

  Neonatal Morbidity     1993-2002         2008-2015         *P*
  ---------------------- ----------------- ----------------- -------
  Surfactant for RDS     155/234 (66.2%)   185/217 (85.3%)   .0001
  Chronic lung disease   90/167 (53.9%)    111/176 (63.1%)   .11
  Home oxygen            15/167 (9.0%)     52/176 (29.5%)    .0001
  PDA ligation           14/167 (8.4%)     19/176 (10.8%)    .57
  Severe ROP             33/167 (19.8%)    34/176 (19.3%)    .92
  Early-onset sepsis     11/234 (4.7%)     8/217 (3.7%)      .76
  Severe IVH             50/234 (21.4%)    26/217 (12.0%)    .01
  NEC (total)            46/234 (19.7%)    17/217 (7.8%)     .0005
  NEC (with surgery)     13/234 (5.6%)     12/217 (5.5%)     .99

Abbreviations: RDS, respiratory distress syndrome; PDA, patent ductus arteriosus; ROP, retinopathy of prematurity; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis.

### Comparison Between 1993-2002 and 2008-2015 Birth Cohorts {#section12-2333794X20901932}

There was statistically significant increase in the use of surfactant replacement in RDS (*P* = .0001) and the use of home oxygen therapy on discharge (*P* = .0001) in the 2008 to 2015 period. The incidence of severe IVH and total number of NEC (*P* = .01 and *P* = .0005, respectively) were significantly decreased in the 2008 to 2015 cohort ([Table 3](#table3-2333794X20901932){ref-type="table"}).

Length of Stay (LOS) in Hospital and Duration of Invasive Mechanical Ventilation Among Survivors {#section13-2333794X20901932}
------------------------------------------------------------------------------------------------

[Table 4](#table4-2333794X20901932){ref-type="table"} shows the LOS in hospital and duration of invasive mechanical ventilation among survivors. Mean LOS in hospitals were 96.3 ± 30.0 days and 96.0 ± 34.8 days in the birth cohort of 2008 to 2011 and 2012 to 2015, respectively. Mean duration of invasive ventilation was 9.8 ± 11.5 days and 9.2 ± 14.6 days in the birth years of 2008 to 2011 and 2012 to 2015, respectively.

###### 

Length of Stay (LOS) and Duration of Invasive Ventilation Among Survivors.

![](10.1177_2333794X20901932-table4)

                                            1993-1996       1997-2002     2008-2011   2012-2015   *P*
  ----------------------------------------- --------------- ------------- ----------- ----------- ---------
  LOS (days)                                                                                      
   Mean ± SD                                112.25 ± 32.0   108.53±41.0   96.3±30.0   96.0±34.8   .001
   Range                                    49-438          51-338        43-219      54-218      
  Duration of invasive ventilation (days)                                                         
   Mean ± SD                                26.7±21.0       16.7±18.2     9.8±11.5    9.2±14.6    \<.0001
   Range                                    0-80            0-84          0-55        0-71        

Abbreviation: SD, standard deviation.

Among the survivors, there was a significant decrease in the mean LOS from 112.25 ± 32.0 days in the period of 1993 to 1996, 108.53 ± 41.0 days in 1997 to 2002, 96.3 ± 30.0 days in 2008 to 2011, to 96.0 ± 34.8 days in 2012 to 2015 (*P* = .001). Mean duration of invasive mechanical ventilation was shortened significantly from 26.7 ± 21.0 days (1993-1996), 16.7 ± 18.2 days (1997-2002), 9.8 ± 11.5 days (2008-2011), to 9.2 ± 14.6 days (2012-2015; *P* \< .0001; [Table 4](#table4-2333794X20901932){ref-type="table"}).

Early Neurodevelopmental Outcomes and Growth of Survivors {#section14-2333794X20901932}
---------------------------------------------------------

One hundred forty-three out of 176 (81%) survivors were assessed at a corrected mean age of 18.1 ± 1.96 months (range = 8.6-28.5 months) for the birth year of 2008 to 2015. [Table 5](#table5-2333794X20901932){ref-type="table"} shows the neurodevelopmental/behavioral and growth problems identified on follow-up. A total of 7.7% (11/143 infants) were diagnosed to have cognitive impairment with an overall DQ of \<2 SD, and 11.9% (17/143 infants) required special education service. A total of 4.2% (6/143 infants) had cerebral palsy, 2.1% (3/143 infants) with profound visual impairment, and 0.7% (1/143 infants) with profound hearing loss. A total of 12.6% (18/143 infants) were diagnosed to have autistic spectrum disorder, 7.7% (11/143 infants) with attention deficit hyperactivity disorder, and 2.1% (3/143 infants) with epilepsy. A total of 15.4% (22/143 infants), 13.3% (19/143 infants), and 11.2% (16/143 infants) having growth failure with body weight, head circumference, and body height \<third percentile, respectively.

###### 

Neurodevelopmental Outcomes and Growth at Corrected Age of 18 to 24 Months.

![](10.1177_2333794X20901932-table5)

                                             1993-2002    2008-2015    *P*
  ------------------------------------------ ------------ ------------ -----
  Survivors                                  167          176          
  Developmental assessment performed         126          143          
  Developmental quotient (overall \<2 SD)    21 (16.7%)   11 (7.7%)    .04
   Locomotor                                 20 (15.9%)   11 (7.7%)    .06
   Personal-social                           20 (15.9%)   8 (5.6%)     .01
   Hearing and speech                        12 (9.5%)    32 (22.4%)   .01
   Coordination                              14 (11.1%)   13 (9.1%)    .73
   Performance                               11 (8.7%)    9 (6.3%)     .60
  Cerebral palsy                             17 (13.5%)   6 (4.2%)     .01
  Profound visual impairment                 13 (10.3%)   3 (2.1%)     .01
  Profound hearing loss                      6 (4.8%)     1 (0.7%)     .09
  Autistic spectrum disorder                 N/A          18 (12.6%)   N/A
  Attention deficit hyperactivity disorder   N/A          11 (7.7%)    N/A
  Need for special education service         24 (19.0%)   17 (11.9%)   .14
  Epilepsy                                   1 (0.79%)    3 (2.1%)     .71
  Growth failure (\<3%)                      N/A                       N/A
   Body weight                                            22 (15.4%)   
   Head circumference                                     19 (13.3%)   
   Body height                                            16 (11.2%)   

Abbreviations: SD, standard deviation; N/A, not available.

Risk factors identified affecting cognition using univariate logistic regression analysis included male sex (*P* = .003), earlier birth years (*P* = .013), and longer duration of invasive ventilation (*P* = .000). Risk factors identified affecting behavior (autistic spectrum disorder or attention deficit hyperactivity disorder) and growth using univariate logistic regression analysis included male sex (*P* = .015) and lower birth weight (*P* = .038), respectively. No significant risk factors could be identified for cerebral palsy, and hearing and visual impairment. [Table 6](#table6-2333794X20901932){ref-type="table"} shows the result of multiple logistic regression analysis.

###### 

Results of Multiple Logistic Regression With Cognitive Impairment and Growth Failure as Outcome Variables.

![](10.1177_2333794X20901932-table6)

                                              Cognitive Impairment   Growth Failure                        
  ------------------------------------------- ---------------------- ---------------- -------------------- ------
  Sex (male)                                  7.29 (1.83-29.02)      .005             NS                   
  Birth years (recent years)                  0.66 (0.50-0.88)       .005             NS                   
  Duration of invasive ventilation (longer)   1.07 (1.03-1.11)       .000             NS                   
  Birth weight (heavier)                      NS                                      0.99 (0.987-0.995)   .000
  Gestational age (more mature)               NS                                      1.52 (1.22-1.89)     .00

Abbreviations: CI, confidence interval; NS, no significant association in univariate analysis.

### Comparison Between 1993-2002 and 2008-2015 Birth Cohorts {#section15-2333794X20901932}

There were significantly lower rates of cerebral palsy (*P* = .01) and visual impairment (*P* = .01) in the 2008 to 2015 cohort ([Table 5](#table5-2333794X20901932){ref-type="table"}). Rate of significant developmental delay defined as an overall DQ of \<2 SD as well as the rate of significant delay in the personal-social subscale were significantly lower in the recent cohort (2018-2015) compared with 1993 to 2002 (*P* = .04 and *P* = .01, respectively). However, delay in the hearing and speech subscale was significantly higher in the recent cohort (*P* = .01). The need for special education service, rate of profound hearing loss, and epilepsy had remained similar over the years.

Discussion {#section16-2333794X20901932}
==========

With advances in obstetric and neonatal care, the survival of ELBW infants has improved dramatically over the past few decades.^[@bibr6-2333794X20901932]^ Our results compared favorably with other international data,^[@bibr2-2333794X20901932]^ with a significant improvement in the overall survival for ELBW infants from 71.4% (1993-2002) to 81.1% (2008-2015), especially in the group with a birth weight of 501 to 750 g. The improvement in perinatal care was supported by a decrease in babies born SGA, increased use of antenatal steroid, more babies born with an Apgar score of \>3 at 1 minute of life, increased use of surfactant therapy, and decreased incidence of severe IVH and NEC.

Among survivors of ELBW in our study, infants were able to be discharged from the hospital earlier, with the mean LOS reduced from 112.25 days to 96.0 days (from 1993-1996 to 2012-2015). This may be attributed by the reduction in the duration of invasive ventilation (from 26.7 days to 9.2 days) and more babies being discharged with home oxygen therapy (from 9% to 29.5%) with time. Shortening of hospital stay also carries an important economy impact with cost savings, reducing burden on the health care system.

Previous studies of neurodevelopmental outcomes among extremely premature infants have shown variable results, with reports of increased,^[@bibr7-2333794X20901932],[@bibr8-2333794X20901932]^ unchanged,^[@bibr9-2333794X20901932][@bibr10-2333794X20901932]-[@bibr11-2333794X20901932]^ or decreased rates of neurodevelopmental impairment over time.^[@bibr12-2333794X20901932],[@bibr13-2333794X20901932]^ In our study, neurodevelopmental outcome at the corrected age of 18 to 24 months has been shown to be better in the past 2 decades. The prevalence of cerebral palsy decreased from 13.5% to 4.2% from 1993-2002 to 2008-2015 birth years. This phenomenon could be partly explained by the decreased incidence of severe IVH. Cerebral palsy rate in our recent cohort compared favorably with international data (8.5% in Vermont Oxford Network^[@bibr2-2333794X20901932]^).

In our study, the proportion of infants with significant developmental delay (with overall DQ of \<2 SD) or significant delay in the personal-social aspects declined significantly from 16.7% to 7.7% and 15.9% to 5.6%, respectively, from birth years 1993-2002 to 2008-2015. Improvement in cognitive outcome could be explained by a reduction in the duration of invasive ventilation, as a longer period of invasive ventilation is found to be a risk factor for cognitive impairment in our study. In recent years, our unit has been managing RDS more with continuous positive airway pressure support with subsequent selective surfactant administration, that is, INSURE (INtubation, SURfactant administration, then Extubation), therefore avoiding unnecessary or prolonged invasive ventilation. However, significantly more infants were having speech delay in recent cohort (22.4% in 2008-2015) compared with 9.5% in 1993 to 2002. This finding is consistent with a recent meta-analysis showing a higher prevalence of autistic spectrum disorder in the preterm population,^[@bibr14-2333794X20901932]^ resulting in impairment in the speech development.

Although the rate of severe ROP has not changed, the rate of visual impairment has declined significantly from 10.3% to 2.1% (from 1993-2002 to 2008-2015). This may have been contributed by the regular surveillance program for ROP in ELBW babies, with early identification of high-risk group and provision of timely intervention for severe ROP, minimizing the risk of visual impairment in the long-term. However, comparing with another recent cohort in the United States,^[@bibr3-2333794X20901932]^ with the rate of profound visual impairment of \<1%, there is room for improvement in our center, for example, stringent titration of oxygen to achieve target saturation to prevent oxygen toxicity.

One limitation of our study is that we only reported on the neurodevelopmental outcome at 18 to 24 months corrected age. Subtle neurocognitive impairment and specific learning disability may not be detected at this early age and longer term follow-up is required. Future directions should include early identification of at-risk children using parental questionnaires, followed by longer term follow-up with standardized evaluation by formal psychometric tests.

In conclusion, we showed an improvement in survival and short-term neurodevelopmental outcome between the birth cohorts of 1993 to 2002 and 2008 to 2015, as a result of an improvement in the perinatal care of these infants over all these years.
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